Veterinarian Access
Reconcile product package
about RECONCILE
Share
FacebookTwitter

About Reconcile®
(fluoxetine hydrochloride)

Reconcile® (fluoxetine hydrochloride) is a once-daily FDA-approved, chewable tablet formulated specifically for dogs for the treatment of canine separation anxiety in conjunction with a behavior modification plan. Reconcile is approved for use in dogs and puppies 6 months of age or older weighing 8.8 lbs or more. It’s available in four tablet strengths, prescribed according to your dog’s weight. Your veterinarian will know which dosage is right for your dog.

Reconcile + BOND: SIMPLE. PROVEN. EFFECTIVE.

In 1 week 42% of dogs show improvement. In 8 weeks 57% of dogs show improvement.Reconcile® is FDA-approved for use in combination with the BOND™ simple training plan, developed by Elanco in collaboration with veterinarians, veterinary behaviorists and pet owners.

In clinical trials, Reconcile combined with behavior modification training produced measurable results. Within 8 weeks, 73% of dogs showed significant improvement as compared to behavior modification alone (51%). Within the first week, 42% of dogs showed improvement as compared to behavior modification alone (18%).1

Studies also show that, taken once daily, Reconcile combined with the BOND behavior modification plan facilitates improvement and greater pet owner satisfaction.2

Together, Reconcile and BOND training promote a positive, easy-to-follow approach to managing separation anxiety.

How to use Reconcile

Reconcile is a once-daily, chewable, flavored tablet prescribed by your veterinarian. You can give it to your dog as you would any other tablet medication. It can be taken with or without food.

A daily dose of Reconcile along with the BOND simple training plan gives you the best chance of success with helping to manage separation anxiety.

If you miss a dose, do not increase or double the next dose. Just continue with the next scheduled dose, as prescribed by your veterinarian.

If you unintentionally give your dog more than the prescribed dose, call your veterinarian for advice.

Learn how your veterinarian can help treat canine separation anxiety.

IMPORTANT SAFETY INFORMATION

The most common adverse events reported in decreasing order of reported frequency are: decreased appetite, depression/lethargy, shaking/shivering/tremor, vomiting, restlessness and anxiety, seizures, aggression, diarrhea, mydriasis, vocalization, weight loss, panting, confusion, incoordination, and hypersalivation.

Reconcile chewable tablets are contraindicated for dogs with epilepsy or a history of seizures; with drugs that lower the seizure threshold; with a monoamine oxidase inhibitor (MAOI) or within a minimum of 14 days of discontinuing therapy with an MAOI; in dogs with a known hypersensitivity to fluoxetine HCl or other SSRIs.

A six—week washout interval should be observed following discontinuation of therapy with Reconcile chewable tablets prior to the administration of any drug that may adversely interact with fluoxetine or norfluoxetine.

View full product label for complete safety information.

REFERENCES

1Reconcile, Freedom of Information Summary, 2007, Study D00901.

2Effects of Reconcile (fluoxetine hydrochloride) chewable tablets plus behavior management for canine separation anxiety. Simpson BS, Landsberg GM, Reisner IR, et al. Vet Ther 8:18–31, 2007.

© 2011 Copyright Elanco | Privacy Statement | Trademark | Terms of Use | Site Map